Canaan Partners VII’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Canaan Partners VII’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-615,350	Closed	-$3.13M	–	3
2016 Q2	$3.13M	Hold	615,350	–	–	2.42%	3
2016 Q1	$13.2M	Hold	615,350	–	–	5.46%	3
2015 Q4	$18.8M	Hold	615,350	–	–	5.84%	2
2015 Q3	$20.5M	Hold	615,350	–	–	4.68%	2
2015 Q2	$28.6M	Hold	615,350	–	–	5.59%	2
2015 Q1	$22.1M	Hold	615,350	–	–	2.36%	2
2014 Q4	$26M	Hold	615,350	–	–	2.07%	3
2014 Q3	$15.9M	Buy	+615,350	New	+$19M	27.16%	3

Other funds holding MRNS

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Canaan Partners VII's MRNS Position: Q3 2016 in Review

Canaan Partners VII sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2016, closing a stake of 615,350 shares — an estimated $3.13M sold.

Canaan Partners VII first reported a position in MRNS in Q3 2014 and held it in 8 quarters. The position peaked at $28.6M in Q2 2015. 26 funds tracked by Wall St. Rank hold MRNS as of Q3 2016.

Canaan Partners VII reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2016 after selling out during the quarter.
Canaan Partners VII sold 615,350 Marinus Pharmaceuticals, Inc shares in Q3 2016, an estimated $3.13M.
Canaan Partners VII first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 8 quarters.
Canaan Partners VII's Marinus Pharmaceuticals, Inc position peaked at $28.6M in Q2 2015.
26 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2016.

Based on Canaan Partners VII's 13F filing for Q3 2016, filed 7 Oct 2016.